Amylyx Reports Positive Early Safety Data for AMX0114 in ALS Phase 1 Trial — Amylyx Pharmaceuticals, Inc.

Event summary

Amylyx presented Phase 1 LUMINA trial data for AMX0114 at ENCALS 2026, showing no drug-related serious adverse events in the lowest dose cohort (12.5 mg).
Biomarker levels (SBDP-145, NfL, pNFH) remained near baseline in Cohort 1.
The trial is evaluating four dose levels; Cohorts 1 and 2 are fully enrolled, with Cohort 3 currently enrolling.
AMX0114 has FDA Fast Track designation for ALS treatment.

The big picture

Amylyx’s positive early safety data for AMX0114 positions it as a potential new therapeutic option in the competitive ALS space, where calpain-2 inhibition represents an emerging mechanism. The trial’s progress aligns with broader industry trends toward targeted antisense therapies for neurodegenerative diseases.

What we're watching

Dose Escalation: Whether higher dose levels will maintain safety and show biomarker changes.
Regulatory Pathway: How the Fast Track designation may accelerate AMX0114's development timeline.
Clinical Efficacy: The pace at which Phase 2 trials could begin based on these results.